Arcus Jumps as ARC-20 Data Show Casdatifan Outperforming Approved HIF-2α Drug
RCUS sits 47% above its 52-week low of $16.35 on elevated volume (2.7× avg).
Summary
Arcus disclosed new ARC-20 data for casdatifan in clear cell renal cell carcinoma, and the stock is up on it. The standout number: 35-month median overall survival in heavily pre-treated late-line patients on casdatifan monotherapy, more than a year better than the only approved HIF-2α inhibitor, Merck's belzutifan. In second-line, casdatifan plus cabozantinib produced 14.5 months median PFS and 77% 18-month survival. Analysts are leaning in — TD Cowen calls casdatifan differentiated with first-line success appearing likely, and Leerink expects a 10%-25% move. This follows the 8-K filed today with the same data and builds on the July HIF-2α collaboration deals with Summit and a second partner. The read is that casdatifan could become a backbone RCC therapy, which matters for a company whose Q2 showed a $91M net loss and falling license revenue.
At the time of this announcement, RCUS was trading at $24.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $16.35 to $31.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.